PnuVax Incorporated is led by Dr. Donald Gerson and is focused on the management of emerging infectious disease worldwide. At the core of the PnuVax approach is biomanufacturing of low-cost vaccines that effectively target the various strains of pneumococcal bacteria associated with childhood and adult pneumonia.

Cost-effective to scale up and distribute, the next generation PnuVax solution employs patented conjugate vaccine technologies that are presently undergoing clinical proof-of-concept trials. With headquarters is Kingston, Canada, PnuVax has an aim of reducing childhood pneumonia incidence in the developing world, as well as in Canada.

In leading PnuVax, Dr. Gerson draws on years of experience overseeing drug manufacturing with pharmaceutical companies such as Wyeth-Lederle Vaccines and Pediatrics. His achievements beyond PnuVax include guiding Celltrion, Inc., in the creation of an FDA-approved cGMP biosimilars production facility in South Korea. Milestones achieved by PnuVax to date include securing a grant from a major foundation that facilitates drug development and biomanufacturing expansion.